This is a StreetInsider.com Premium Only Page

BioCryst Pharma (BCRX) – StreetInsider.com Reports

Apr 17, 2024 05:37 AM BioCryst Pharma (BCRX) Announces Approval of ORLADEYO in Brazil

Feb 27, 2024 05:09 PM BioCryst Pharma (BCRX) Files Mixed Shelf

Feb 26, 2024 07:57 AM BioCryst Pharma (BCRX) Misses Q4 EPS by 3c ; Offers Guidance

Feb 23, 2024 07:01 AM BioCryst Pharma (BCRX) Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO Treatment

Jan 8, 2024 01:41 AM BioCryst Pharma (BCRX) PT Lowered to $14 at JMP Securities

Jan 5, 2024 04:02 PM BioCryst Pharma (BCRX) Reports Prelim FY23 ORLADEYO Sales of $325M

Dec 19, 2023 07:02 AM BioCryst Pharma (BCRX) Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO

Nov 21, 2023 07:01 AM BioCryst Pharma (BCRX) Launches ORLADEYO in Spain

Nov 20, 2023 03:59 AM JPMorgan Reinstates BioCryst Pharma (BCRX) at Overweight

Nov 6, 2023 09:46 AM BioCryst Pharma (BCRX) PT Raised to $11 at BofA Securities

Nov 3, 2023 03:30 AM BioCryst Pharma (BCRX) PT Lowered to $10 at Jefferies

Nov 3, 2023 02:59 AM BioCryst Pharma (BCRX) PT Lowered to $6 at Barclays

Nov 2, 2023 07:15 AM BioCryst Pharma (BCRX) Tops Q3 EPS by 6c, provides outlook

Sep 18, 2023 07:02 AM BioCryst Pharma (BCRX) Announces INESSS Recommends Public Reimbursement for ORLADEYO

Sep 18, 2023 06:18 AM RBC Capital Upgrades BioCryst Pharma (BCRX) to Outperform, 'Doc Survey Suggesting Good Orladeyo Metrics'

Aug 4, 2023 07:12 AM Jefferies Upgrades BioCryst Pharma (BCRX) to Buy

Aug 4, 2023 06:25 AM BioCryst Pharma (BCRX) PT Raised to $9 at RBC Capital

Aug 3, 2023 07:04 AM BioCryst Pharma (BCRX) Misses Q2 EPS by 1c

Jul 19, 2023 07:02 AM BioCryst Pharma (BCRX) Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO (berotralstat) in Turkey

Jul 13, 2023 06:18 AM BofA Securities Upgrades BioCryst Pharma (BCRX) to Buy on Pullback

May 22, 2023 07:01 AM BioCryst Pharma (BCRX) Announces Approval of ORLADEYO in Chile

May 3, 2023 07:08 AM BioCryst Pharma (BCRX) Tops Q1 EPS by 2c

Apr 27, 2023 07:03 AM BioCryst Pharma (BCRX) Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO

Apr 24, 2023 06:21 AM BioCryst Pharma (BCRX) PT Lowered to $10 at BofA Securities

Apr 20, 2023 05:59 AM BioCryst Pharma (BCRX) PT Lowered to $10 at Evercore ISI

Apr 18, 2023 07:03 AM BioCryst Pharma (BCRX) Refinances Existing Debt with New $450M Financing Commitment

Mar 31, 2023 07:00 AM BioCryst Pharma (BCRX) Appoints Nancy Hutson as Board Chair

Mar 8, 2023 03:02 PM BioCryst Pharma (BCRX) Announces CADTH Recommends Reimbursement for ORLADEYO for Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

Feb 24, 2023 07:02 AM BioCryst Pharma (BCRX) Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO

Feb 23, 2023 03:32 AM BioCryst Pharma (BCRX) PT Lowered to $13 at Evercore ISI

Feb 22, 2023 03:58 PM Today's most important upgrades

Feb 22, 2023 07:17 AM Needham & Company Upgrades BioCryst Pharma (BCRX) to Buy, 'Pipeline Setback Provides Attractive Entry Opportunity'

Feb 22, 2023 05:02 AM BioCryst Pharma (BCRX) PT Lowered to $13 at JPMorgan

Feb 21, 2023 07:06 AM BioCryst Pharma (BCRX) Misses Q4 EPS by 23c

Jan 9, 2023 07:08 AM BioCryst Pharma (BCRX) Reports Prelim FY22 ORLADEYO Sales

Jan 9, 2023 07:04 AM BioCryst Pharma (BCRX) Reports Initial Clinical Data for BCX10013

Dec 16, 2022 06:10 AM BioCryst Pharma (BCRX) PT Lowered to $12 at BofA Securities

Dec 16, 2022 06:10 AM BioCryst Pharma (BCRX) PT Lowered to $10 at Barclays

Dec 15, 2022 07:03 AM BioCryst Pharma (BCRX) Discontinues BCX9930, Focuses on BCX10013

Nov 28, 2022 07:03 AM BioCryst Pharma (BCRX) Announces Approval of ORLADEYO by the Israeli Ministry of Health

Nov 10, 2022 08:06 AM BioCryst Pharma (BCRX) Presents Real-World Data Showing HAE Attack Rate Reduction with ORLADEYO

Nov 2, 2022 07:01 AM BioCryst Pharma (BCRX) PT Lowered to $12 at Barclays

Nov 2, 2022 06:42 AM BioCryst Pharma (BCRX) PT Lowered to $13 at RBC Capital

Nov 2, 2022 06:29 AM UPDATE: Evercore ISI Upgrades BioCryst Pharma (BCRX) to Outperform

Sep 14, 2022 04:02 PM BioCryst Pharma (BCRX) Appoints Bill Sheridan as Chief Development Officer, Ryan Arnold as Chief Medical Officer

Sep 2, 2022 02:46 AM BioCryst Pharma (BCRX) PT Lowered to $21 at JMP Securities

Aug 31, 2022 07:03 AM BioCryst Pharma (BCRX) Granted Orphan Drug Designation for BCX9250

Aug 29, 2022 02:48 PM BioCryst Pharma (BCRX) granted FDA Orphan Drug Designations for treatment of fibrodysplasia ossificans progressiva

Aug 25, 2022 07:04 AM BioCryst Pharma (BCRX) Reports US Govt Exercised Option to Purchase Additional RAPIVAB

Aug 18, 2022 07:01 AM BioCryst Pharma's (BCRX) ORLADEYO Approved in Saudi Arabia